Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections
Sign Up to like & getrecommendations! Published in 2022 at "Medicina"
DOI: 10.3390/medicina58091180
Abstract: Background and Objectives: Brolucizumab is a novel anti-vascular endothelial growth factor (VEGF), whose efficacy has been shown in the Hawk and Harrier phase 3 clinical studies. The goal of the present case series is to… read more here.
Keywords: early octa; outer retina; octa changes; intravitreal injections ... See more keywords